Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports
Go Back
View Our Subscription Options

Search

Descriptive Alt Text

Filters

Showing results 4,201–4,208 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
Verastem Inc. VS-6766 plus avutometinib and defactinib - (RAMP 301) Low-grade serous ovarian cancer (LGSOC) Phase 3 Enrollment Conclusion Oral Oncology
Verastem Inc. Avutometinib in Combination with Defactinib - (RAMP 201) Low-Grade Serous Ovarian Cancer Phase 2 Data Released Oral Oncology
Verastem Inc. COPIKTRA (duvelisib) Rheumatoid arthritis Phase 2 Trial Discontinued oral Immunology: Anti-TNF
Verastem Inc. COPIKTRA (duvelisib) - (DYNAMO) Indolent non-Hodgkin lymphoma Phase 2 Trial Discontinued Oral Oncology
Verastem Inc. VS-6766 and defactinib - (RAMP 202) KRAS mutant non-small cell lung cancer (NSCLC) Phase 2 Trial Discontinued Oral Oncology
Verastem Inc. VS-6063 Mesothelioma prior to surgery Phase 2 Trial Discontinued oral Oncology
Vericel Corporation ixmyelocel-T Stem cells - Dilated Cardiomyopathy Phase 2b Trial Completed Intramuscular Cardiology
Vericel Corporation ixmyelocel-T Stem cells - Dilated Cardiomyopathy Phase 2b Trial Completed Intramuscular Cardiology
1…524525526527528…553
Your trusted source for drug reimbursement data and buy-and-bill insights.
Platform
Resources
Tools
Search Drugs
Newsletter
Reimbursement updates, drug pricing news.
© 2026 BuyandBill.com, All Rights Reserved.
HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, America's Health Insurance Plans, and Blue Cross and Blue Shield Association). CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.